Companies: 10,795·Total market cap: $144.5T
Medite Cancer Diagnostics, Inc.

Medite Cancer Diagnostics, Inc.

MDITOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$8672
P/E Ratio
52W High$0.005
52W Low$0.0001

Medite Cancer Diagnostics, Inc. (MDIT) · Income Statement

Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.

FMP · MDIT · as of 2026-06-09

Financial statements

Revenue · Gross Profit · Net Income
Breakdown2017-122016-122015-12
Revenue
Revenue$6.81M$9.24M$9.89M
Cost of Revenue$6.94M$5.82M$6.26M
Gross Profit($0.13M)$3.42M$3.63M
Gross Margin %(computed)-1.92%36.98%36.67%
Operating Expenses
R&D Expenses$1.19M$1.48M$1.28M
G&A Expenses$0.00M$0.00M$0.00M
Total Operating Expenses$6.35M$5.08M$4.22M
Operating Income($6.48M)($1.66M)($0.60M)
Operating Margin %(computed)-95.11%-17.98%-6.06%
Interest Income$0.00M$0.00M$0.00M
Interest Expense$0.85M$0.69M$0.20M
Income Before Tax($7.30M)($2.29M)($0.78M)
Income Tax Expense($0.49M)($0.13M)$0.08M
Net Income($6.81M)($2.16M)($0.86M)
Net Margin %(computed)-99.97%-23.41%-8.69%
Per Share & EBITDA
EPS (Basic)$-0.26$-0.10$-0.04
Wtd Avg Shares26.44M21.42M20.19M
EBITDA($6.19M)($1.45M)($0.42M)
EBITDA Margin %(computed)-90.81%-15.66%-4.27%

Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M

Explore more Medite Cancer Diagnostics, Inc. data

About Medite Cancer Diagnostics, Inc. (MDIT) Income Statement

Medite Cancer Diagnostics, Inc. (MDIT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2017, MDIT reported revenue of $0.01B, gross profit of ($0.00B) (gross margin -1.92%), and net income of ($0.01B) — a net profit margin of -99.97%.

Frequently asked questions

MDIT · 4 questions

Medite Cancer Diagnostics, Inc. (MDIT) reported revenue of $0.01B for 2017, down 26.3% year-over-year.

MDIT revenueMDIT salesannual revenue YoYincome statement

· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09